Comparative Pharmacology
Head-to-head clinical analysis: KEFLIN versus KEFZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLIN versus KEFZOL.
KEFLIN vs KEFZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic